Some diabetes patients this year have had trouble finding their preferred insulin brands as major drug manufacturers reported shortages of the medicine. USA TODAY set out to find out what patients ...

Now, scientists have made a major breakthrough in developing what has been long called the “holy grail” diabetes treatments — a “smart” insulin that responds in real time to fluctuations in one’s ...

A new treatment combining ReCET and semaglutide eliminated insulin use in 86% of type 2 diabetes patients, improving natural insulin sensitivity. A new treatment combining ReCET and semaglutide could ...

“Notably, glucose values vary over a narrow range (from approximately 2 to 20-30 mM [36 mg/dL to 360-540 mg/dL] in people with diabetes), so a rather steep change in insulin bioactivity must be ...

In a pig model of diabetes, the hypoglycaemia produced by human insulin was not seen when NNC2215 was injected. Finally, rats that lacked insulin were used to investigate the glucose-induced ...

A team led by Novo Nordisk’s Rita Slaaby developed the glucose-responsive insulin, which is called NNC2215. The insulin in NNC2215 makes links to two moieties: a glucose-binding macrocycle and a ...

86% of type 2 diabetes patients treated with a new procedure no longer needed insulin throughout the two-year-long study they participated in. That procedure could be a real game changer for ...

GLP-1R, also known as glucagon-like peptide-1 receptor, is an important target in various medical applications because of its significant role in glucose metabolism and insulin secretion ... the ...